- 2022 - 2026 双極性障害エピゲノムマーカーと薬剤反応性についての検討
- 2022 - 2025 Development of Alzheimer disease biomarker
- 2017 - 2020 幹細胞技術と遺伝子編集技術を組み合わせアルツハイマー病治療戦略を洗練させる
- 2014 - 2018 Intramembrane proteolysis of beta-APP in a gamma-secretase independent mechanism
- 2014 - 2017 Mechanism of presenilin/gamma secretase to produce amyloid beta
- 2013 - 2016 Identification of molecules related to modulation of Amyloid beta production in human cerebrospinal fluid (CSF)
- 2013 - 2016 Increase in Abeta42 production and accelerated dissociation of Abeta42 from gamma-secretase
- 2012 - 2015 Pathogenesis of tauopathies in terms of protein quality control mechanism
- 2011 - 2013 Analysis of presenilin gamma-secretase function on Abeta and NICD generation
- 2011 - 2013 Analysis of novel Alzheimer's disease-related peptides in human cerebrospinal fluid derived from APLP2
- 2010 - 2012 Mass spectrometry analysis of human cerebrospinal fluid with psychiatric disease patients.
- 2008 - 2010 Development of methods to promote degradation of amyloid beta
- 2005 - 2010 アルツハイマー病の早期診断治療法開発
- 2009 - アミロイドベータの分解を促進する方法の開発
- 2009 - プレセニリンγセクレターゼによる膜内蛋白分解機構の解析
- 2009 - プレセニリンγセクレターゼによるNICD産生メカニズムの解析
- 2009 - プレセニリン/γセクレターゼによる切断機構の解析-副作用の少ないアルツハイマー病根本治療薬開発を目指して
- 2009 - アルツハイマー病関連遺伝子解析研究に基づく診断・治療法開発
- 2007 - 2008 Characterization of Abeta-like peptide other in brains of Alzheimer disease
- 2006 - 2007 Characterization of BACE-mediated proteolysis including amyloid-beta
- 2006 - 2007 The mechanisms of anti-Alzheimer dicaam effects by NSAIDs
- 2005 - 2006 Analysis of sequential endoproteolytic process of beta-APP to establish novel therapeutic interventions
- 2005 - 2006 Implication of ER stress in amyloid production and its application for therapeutic approach
- 2004 - 2005 Degradation of amyloid-beta
- 2004 - 2005 Measurement of novel Nβ species level as a substitute for Aβ species.
- 2004 - アミロイドベータは細胞内でどのように分解されるのか?
- 2003 - プレセニリンγセクレターゼの切断プロセスの解析
- -
Show all